Holen Sie sich die Stockscreener-App
52.14
4.16%
2.08
Handel nachbörslich:
52.55
0.41
+0.79%
Schlusskurs vom Vortag:
$50.06
Offen:
$50
24-Stunden-Volumen:
1.23M
Relative Volume:
1.48
Marktkapitalisierung:
$5.24B
Einnahmen:
$523.53M
Nettoeinkommen (Verlust:
$118.02M
KGV:
64.37
EPS:
0.81
Netto-Cashflow:
$124.84M
1W Leistung:
+8.15%
1M Leistung:
+14.77%
6M Leistung:
+112.64%
1J Leistung:
+103.51%
1-Tages-Spanne:
$49.51
$52.35
1-Wochen-Bereich:
$42.01
$52.35
52-Wochen-Spanne:
$20.84
$52.35
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
149 COMMONWEALTH DRIVE, MENLO PARK
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Here is Why Growth Investors Should Buy Corcept (CORT) Now - Yahoo Finance
Corcept (CORT) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance Australia
Corcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher? - RTTNews
Roman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Creative Planning Acquires 841 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year HighStill a Buy? - MarketBeat
Corcept Therapeutics stock soars to all-time high of $50.23 By Investing.com - Investing.com Australia
Corcept Therapeutics stock soars to all-time high of $50.23 - Investing.com
Wall Street Analysts Believe Corcept (CORT) Could Rally 56.66%: Here's is How to Trade - Yahoo Canada Finance
Recent Price Trend in Corcept (CORT) is Your Friend, Here's Why - Yahoo Canada Finance
What is HC Wainwright’s Forecast for CORT FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for CORT FY2024 Earnings - MarketBeat
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View - MSN
Corcept Therapeutics (CORT) Stock Declines Amid Market Activity - GuruFocus.com
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy? - MSN
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2%Here's What Happened - MarketBeat
FY2026 Earnings Estimate for CORT Issued By HC Wainwright - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2024 Earnings Call Transcript - Insider Monkey
Corcept’s relacorilant GRADIENT trial misses primary endpoint - Yahoo Finance
Corcept Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Corcept Therapeutics reports robust Q3 growth, raises guidance - Investing.com Canada
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Corcept Therapeutics Inc (CORT) Q3 2024 Earnings: EPS of $0.41 B - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates - MSN
Corcept: Q3 Earnings Snapshot - Milford Mirror
Corcept reports robust revenue growth in Q3 By Investing.com - Investing.com Canada
abrdn plc Purchases 142,310 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update - StockTitan
Earnings Preview: Corcept Therapeutics - Benzinga
Boston Trust Walden Corp Sells 69,924 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (CORT) Set to Announce Earnings on Wednesday - MarketBeat
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength? - MSN
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise - Yahoo Finance
Corcept stock stays a buy, with analyst eyeing validation of relacorilant’s cancer-fighting mechanism - Investing.com UK
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) PT at $65.25 - Defense World
Corcept Therapeutics Incorporated (NASDAQ:CORT) Position Reduced by Exchange Traded Concepts LLC - Defense World
Exchange Traded Concepts LLC Decreases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Corcept Therapeutics (CORT) Stock Jumps Over 5% Amid Solid Finan - GuruFocus.com
HC Wainwright Increases Corcept Therapeutics (NASDAQ:CORT) Price Target to $80.00 - MarketBeat
Corcept Therapeutics stock target raised, buy rating on Cushing's franchise growth - Investing.com Canada
Key Takeaways From Corcept Therapeutics Analyst Ratings - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month HighHere's Why - MarketBeat
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High? - Yahoo Finance
Corcept Therapeutics stock hits all-time high at $47.81 - Investing.com
Corcept Therapeutics stock hits all-time high at $47.81 By Investing.com - Investing.com UK
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):